ProMIS Neurosciences Inc.

Contributing Author

Recent Articles by ProMIS Neurosciences Inc.

Dec-10	ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk PMN GlobeNewswire
Dec-01	ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 PMN GlobeNewswire
Dec-01	ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference PMN GlobeNewswire
Nov-24	ProMIS Neurosciences Announces Reverse Stock Split PMN GlobeNewswire
Nov-12	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights PMN GlobeNewswire
Nov-03	ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference PMN GlobeNewswire
Oct-22	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group PMN GlobeNewswire
Sep-03	ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 PMN GlobeNewswire
Aug-13	ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights PMN GlobeNewswire
Jul-29	ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference PMN GlobeNewswire
Jul-28	ProMIS Neurosciences Announces Private Placement Financing PMN GlobeNewswire
Jul-22	ProMIS Neurosciences Announces Private Placement Financing PMN GlobeNewswire
Jul-22	ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules PMN GlobeNewswire
Jul-21	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease PMN GlobeNewswire
Jul-21	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease PMN GlobeNewswire
Jun-17	ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference PMN GlobeNewswire
May-12	ProMIS Neurosciences Announces First Quarter 2025 Financial Results PMN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.